Can Eli Lilly Beat These Numbers?
Eli Lilly (NYS: LLY) is expected to report Q4 earnings on Jan. 29. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Eli Lilly's revenues will wane -3.8% and EPS will wane -9.2%.
The average estimate for revenue is $5.81 billion. On the bottom line, the average EPS estimate is $0.79.
Last quarter, Eli Lilly logged revenue of $5.44 billion. GAAP reported sales were 11% lower than the prior-year quarter's $6.15 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.79. GAAP EPS of $1.18 for Q3 were 6.3% higher than the prior-year quarter's $1.11 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.9%, 30 basis points worse than the prior-year quarter. Operating margin was 20.9%, 530 basis points worse than the prior-year quarter. Net margin was 24.4%, 430 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $22.46 billion. The average EPS estimate is $3.33.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,258 members out of 1,354 rating the stock outperform, and 96 members rating it underperform. Among 429 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 405 give Eli Lilly a green thumbs-up, and 24 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eli Lilly is hold, with an average price target of $44.47.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Eli Lilly. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Eli Lilly to My Watchlist.
The article Can Eli Lilly Beat These Numbers? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.